CD8A and neoplasm: In a melanoma mouse model, co-administration of Poly[I:C] and FLT3L enhanced CD103+ DC expansion and CD8+ T-cell recruitment at the tumor site and synergized PD-L1 antitumor activity (Salmon et al., 2016).